Want to see GKOS full AI Analyst Report?

Glaukos (GKOS) Stock Forecast & Price Target

426 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GKOS Analyst Ratings

Strong Buy

13 Buy

1 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Glaukos

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GKOS Stock 12 Month Forecast

Average Price Target

$185.83

▲(21.00% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is $185.83 with a high forecast of $215.00 and a low forecast of $153.00. The average price target represents a 21.00% change from the last price of $153.58.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"82":"$82","149":"$149","216":"$216","115.5":"$115.5","182.5":"$182.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":215,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$215.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":185.83333333333331,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$185.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":153,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$153.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[82,115.5,149,182.5,216],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.72,170.43384615384616,174.1476923076923,177.86153846153846,181.57538461538462,185.28923076923076,189.00307692307692,192.71692307692308,196.43076923076922,200.14461538461538,203.85846153846154,207.57230769230767,211.28615384615384,{"y":215,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.72,168.1902564102564,169.66051282051282,171.13076923076923,172.60102564102564,174.07128205128205,175.54153846153844,177.01179487179485,178.48205128205126,179.95230769230767,181.42256410256408,182.8928205128205,184.3630769230769,{"y":185.83333333333331,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.72,165.6646153846154,164.60923076923078,163.55384615384617,162.49846153846153,161.44307692307692,160.3876923076923,159.3323076923077,158.27692307692308,157.22153846153847,156.16615384615383,155.11076923076922,154.0553846153846,{"y":153,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":86.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.91,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.47,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.12,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.64,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.22,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.12,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.57,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.72,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$215.00

Average Price Target$185.83

Lowest Price Target$153.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anthony Petrone

Mizuho Securities

$185

Buy

20.46%

Upside

Reiterated

07/31/26

Mizuho Securities Sticks to Their Buy Rating for Glaukos (GKOS)

Steven Lichtman

William Blair

―

Buy

―

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (NASDAQ: ADPT), Viking Therapeutics (NASDAQ: VKTX) and Glaukos (NYSE: GKOS)

Richard Newitter

Truist Financial

$180→$215

Buy

39.99%

Upside

Reiterated

07/30/26

Truist Financial Keeps Their Buy Rating on Glaukos (GKOS)

Thomas Stephan

Stifel Nicolaus

$175→$190

Buy

23.71%

Upside

Assigned

07/30/26

Stifel Nicolaus Sticks to Their Buy Rating for Glaukos (GKOS)

Larry Biegelsen

Wells Fargo

$138→$178

Buy

15.90%

Upside

Assigned

07/30/26

Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Humana (HUM)

Ryan Zimmerman

BTIG

$164→$193

Buy

25.67%

Upside

Reiterated

07/30/26

Glaukos Earns Reiterated Buy, Top Pick Rating as Strong Execution Drives Upward Price Target Revision to $193

Joanne Wuensch

Citi

$175→$188

Buy

22.41%

Upside

Reiterated

07/30/26

Glaukos price target raised to $188 from $175 at CitiGlaukos price target raised to $188 from $175 at Citi

David Saxon

Needham

$150→$201

Buy

30.88%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Glaukos (NYSE: GKOS) and MannKind (NASDAQ: MNKD)

Patrick Wood

UBS

$150→$172

Hold

11.99%

Upside

Reiterated

07/30/26

Glaukos assumed with Neutral from Buy at UBSGlaukos assumed with Neutral from Buy at UBS

Yi Chen

H.C. Wainwright

$168→$195

Buy

26.97%

Upside

Reiterated

07/30/26

Glaukos price target raised to $195 from $168 at H.C. WainwrightGlaukos price target raised to $195 from $168 at H.C. Wainwright

Matthew O'Brien

Piper Sandler

$165→$195

Buy

26.97%

Upside

Reiterated

07/30/26

Piper Sandler Sticks to Their Buy Rating for Glaukos (GKOS)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$165

Buy

7.44%

Upside

Reiterated

06/23/26

Jefferies Remains a Buy on Glaukos (GKOS)

Allen Gong

J.P. Morgan

―

Buy

―

Reiterated

06/05/26

Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA) and Glaukos (NYSE: GKOS)

David Roman

Goldman Sachs

$153

Buy

-0.38%

Downside

Reiterated

05/25/26

Goldman Sachs Reaffirms Their Buy Rating on Glaukos (GKOS)

Mason Carrico

Stephens

$115→$145

Buy

-5.59%

Downside

Reiterated

01/02/26

Glaukos price target raised to $145 from $115 at StephensGlaukos price target raised to $145 from $115 at Stephens

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anthony Petrone

Mizuho Securities

$185

Buy

20.46%

Upside

Reiterated

07/31/26

Mizuho Securities Sticks to Their Buy Rating for Glaukos (GKOS)

Steven Lichtman

William Blair

―

Buy

―

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (NASDAQ: ADPT), Viking Therapeutics (NASDAQ: VKTX) and Glaukos (NYSE: GKOS)

Richard Newitter

Truist Financial

$180→$215

Buy

39.99%

Upside

Reiterated

07/30/26

Truist Financial Keeps Their Buy Rating on Glaukos (GKOS)

Thomas Stephan

Stifel Nicolaus

$175→$190

Buy

23.71%

Upside

Assigned

07/30/26

Stifel Nicolaus Sticks to Their Buy Rating for Glaukos (GKOS)

Larry Biegelsen

Wells Fargo

$138→$178

Buy

15.90%

Upside

Assigned

07/30/26

Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Humana (HUM)

Ryan Zimmerman

BTIG

$164→$193

Buy

25.67%

Upside

Reiterated

07/30/26

Glaukos Earns Reiterated Buy, Top Pick Rating as Strong Execution Drives Upward Price Target Revision to $193

Joanne Wuensch

Citi

$175→$188

Buy

22.41%

Upside

Reiterated

07/30/26

Glaukos price target raised to $188 from $175 at CitiGlaukos price target raised to $188 from $175 at Citi

David Saxon

Needham

$150→$201

Buy

30.88%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Glaukos (NYSE: GKOS) and MannKind (NASDAQ: MNKD)

Patrick Wood

UBS

$150→$172

Hold

11.99%

Upside

Reiterated

07/30/26

Glaukos assumed with Neutral from Buy at UBSGlaukos assumed with Neutral from Buy at UBS

Yi Chen

H.C. Wainwright

$168→$195

Buy

26.97%

Upside

Reiterated

07/30/26

Glaukos price target raised to $195 from $168 at H.C. WainwrightGlaukos price target raised to $195 from $168 at H.C. Wainwright

Matthew O'Brien

Piper Sandler

$165→$195

Buy

26.97%

Upside

Reiterated

07/30/26

Piper Sandler Sticks to Their Buy Rating for Glaukos (GKOS)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$165

Buy

7.44%

Upside

Reiterated

06/23/26

Jefferies Remains a Buy on Glaukos (GKOS)

Allen Gong

J.P. Morgan

―

Buy

―

Reiterated

06/05/26

Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA) and Glaukos (NYSE: GKOS)

David Roman

Goldman Sachs

$153

Buy

-0.38%

Downside

Reiterated

05/25/26

Goldman Sachs Reaffirms Their Buy Rating on Glaukos (GKOS)

Mason Carrico

Stephens

$115→$145

Buy

-5.59%

Downside

Reiterated

01/02/26

Glaukos price target raised to $145 from $115 at StephensGlaukos price target raised to $145 from $115 at Stephens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Glaukos

3 Months

Allen GongJ.P. Morgan

Success Rate

13/15 ratings generated profit

Average Return

+11.27%

Copying Allen Gong's trades and holding each position for 3 Months would result in 86.67% of your transactions generating a profit, with an average return of +11.27% per trade.

1 Year

Joanne WuenschCiti

Success Rate

14/16 ratings generated profit

Average Return

+38.99%

Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +38.99% per trade.

2 Years

David SaxonNeedham

Success Rate

24/24 ratings generated profit

Average Return

+66.78%

Copying David Saxon's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +66.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GKOS Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GKOS has received 28 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. GKOS average Analyst price target in the past 3 months is 185.83.

Each month's total comprises the sum of three months' worth of ratings.

GKOS Financial Forecast

GKOS Earnings Forecast

Next quarter’s earnings estimate for GKOS is -$0.10 with a range of -$0.18 to -$0.03. The previous quarter’s EPS was -$0.14. GKOS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.85% of the time in the same period. In the last calendar year GKOS has Performed in-line its overall industry.

GKOS Sales Forecast

Next quarter’s sales forecast for GKOS is $167.68M with a range of $160.13M to $174.00M. The previous quarter’s sales results were $185.61M. GKOS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.33% of the time in the same period. In the last calendar year GKOS has Performed in-line its overall industry.

GKOS Stock Forecast FAQ

What is GKOS’s average 12-month price target, according to analysts?

Based on analyst ratings, Glaukos’s 12-month average price target is 185.83.

What is GKOS’s upside potential, based on the analysts’ average price target?

Glaukos has 21.00% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GKOS a Buy, Sell or Hold?

Glaukos has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.

What is Glaukos’s price target?

The average price target for Glaukos is 185.83. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $215.00 ,the lowest forecast is $153.00. The average price target represents 21.00% Increase from the current price of $153.58.

What do analysts say about Glaukos?

Glaukos’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of GKOS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Glaukos (GKOS) Stock Forecast & Price Target

GKOS Analyst Ratings

GKOS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Glaukos

GKOS Analyst Recommendation Trends

GKOS Financial Forecast

GKOS Earnings Forecast

GKOS Sales Forecast

GKOS Stock Forecast FAQ

Detailed List of Analyst Forecasts